We recently found that overexpression of p185 c-erbB2 in cerbB2 transfected MDA-MB-435 breast cancer cells (435.eB transfectants) confers a 5 ± 9-fold increase in Taxol resistance. To examine whether Taxol resistance is a common phenomenon in other c-erbB2 overexpressing breast cancer cell lines, we tested a panel of human breast cancer cell lines established from dierent patients and expressing p185 c-erbB2 at dierent levels for their sensitivity to Taxol and Taxotere, a synthetic taxoid. Higher expression of p185 c-erbB2 in these breast cancer cell lines indeed correlated well with resistance to Taxol and Taxotere, and the degree of resistance was about 100-fold that in c-erbB2-overexpressing 435.eB transfectants, demonstrating that these breast cancer cells are highly resistant to Taxol. Since mdr-1-encoded p-glycoprotein (p170 mdr-1 ) has been implicated in Taxol resistance, we next examined the p170 mdr-1 levels in these breast cancer cell lines that are highly resistant to Taxol. Higher levels of p170 mdr-1 expression were found in several breast cancer cell lines that are highly resistant to Taxol. Since these same breast cancer cell lines also expressed higher levels of p185 c-erbB2
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Introduction
The c-erbB2 gene (also known as HER-2, neu or NGL) encodes a 185 kDa (p185 c-erbB2 ) transmembrane glycoprotein with intrinsic tyrosine kinase activity Coussens et al., 1985; Stern et al., 1986) . p185
c-erbB2 has extensive sequence homology to the epidermal growth factor receptor (EGFR) (Bargmann et al., 1986; Yamamoto et al., 1986) . Ampli®cation/overexpression of c-erbB2 has been found in approximately 30% of breast cancers (Slamon et al., 1987) . Patients whose breast cancers overexpress c-erbB2 have a signi®cantly poorer prognosis than patients whose tumors do not overexpress the oncogene. Moreover high levels of expression of p185 c-erbB2 have been positively correlated with lymph node metastasis of breast cancers (Lacroix et al., 1989; Slamon et al., 1987; Tauchi et al., 1989) . We recently demonstrated that overexpression of p185 c-erbB2 enhances the metastatic potential of human breast cancer cells (Tan et al., 1997) . Additionally, several studies have demonstrated a possible relationship between chemosensitivity and p185 c-erbB2 expression in breast cancers (Arteaga et al., 1994; Gusterson et al., 1992; Hancock et al., 1991; Muss et al., 1994; Pietras et al., 1994) . Consistent with this notion, we found that introduction of c-erbB2 into MDA-MB-435 cells (named 435.eB transfectants) conferred increased resistance to Taxol (Yu et al., 1996) , a chemotherapeutic agent that has been shown to be highly eective in treating advanced metastatic breast cancers in several phase I and phase II clinical trials (Chevalier et al., 1995; Holmes et al., 1991) . These ®ndings led us to hypothesize that overexpression of p185 c-erbB2 leads to higher metastatic potential and increased drug resistance in human breast cancers, thereby resulting in a poor clinical outcome for breast cancer patients with p185
c-erbB2 overexpressing tumor. In this study, we investigated whether the relation between c-erbB2 overexpression and Taxol resistance is of more general signi®cance. We tested Taxol and Taxotere sensitivity in a panel of human breast cancer cell lines that were established from tumors of dierent breast cancer patients and known to express p185 c-erbB2 at dierent levels. We found that a higher level of p185 c-erbB2 expression in the panel of established breast cancer cell lines indeed contributed to increased resistance to Taxol and Taxotere. In addition, we found that co-overexpression of p170 mdr-1 with p185 c-erbB2 rendered these breast cancer cells highly resistant to Taxol.
Results

Higher p185
c-erbB2 level correlates with increased resistance to Taxol and Taxotere in multiple breast cancer cell lines
To investigate whether Taxol resistance is a general phenomenon in c-erbB2-overexpressing breast cancer cells, we tested Taxol sensitivity in a panel of human breast cancer cell lines that were established from dierent patients, including seven human breast cancer cell lines known to express c-erbB2 mRNA at dierent levels. A human breast cell line, HBL-100, that expresses very low levels of p185 c-erbB2 was included as a control. To determine the p185 c-erbB2 protein levels in these cell lines, we performed Western blotting analysis using the c-neu-Ab-3 anti-p185 monoclonal antibody. As Figure 1a demonstrates, these cell lines expressed the p185 c-erbB2 protein at dierent levels, that generally correlated with the previously reported relative c-erbB2 mRNA levels in these cell lines (Kraus et al., 1987) ( Table 1 ), except that the p185 level in BT483 cells was higher than predicted from the mRNA level. It is possible that the BT483 subclones used in this study dier from that used in the previous investigation by Kraus and coworkers (Kraus et al., 1987; Miller et al., 1994) .
We then performed cytotoxicity assays on these cell lines to determine their chemosensitivity to Taxol. Cells were grown in the presence of dierent concentrations of Taxol, and the percentages of viable cells relative to the drug-free control were determined by the CellTiter96 TM AQ nonradioactive cell proliferation assay (Promega Corp). As Figure 1b shows, the breast cancer cells that produced more p185 c-erbB2 (i.e. SKBR-3, BT483, MDA-MB-453, MDA-MB-361, and BT-474) were generally more resistant to Taxol than those producing less p185 c-erbB2 (HBL-100, MDA-MB-231, and MDA-MB-435) (Figure 1a) . Similarly, p185 c-erbB2 -overexpressing breast cancer cells were also more resistant to Taxotere, a synthetic taxoid, than those that expressed lower levels of p185 c-erbB2 ( Figure 1c ). -overexpressing breast cancer cells, which further supports our previous ®nding that overexpression of p185 c-erbB2 in 435.eB transfectants conferred increased Taxol resistance.
Interestingly, the BT483, MDA-MB-453, MDA-MB-361, SKBR-3, and BT474 cells demonstrated more than 100-fold the Taxol resistance as did HBL-100, MDA-MB-231 and MDA-MB-435 cells ( Figure 1 and Table 1 ). However, the 435.eB1 transfectants, which expressed similar or high levels of p185 c-erbB2 as BT483, MDA-MB-453, MDA-MB-361, SKBR-3 and BT474 cells, only demonstrated 5 ± 9-fold the Taxol resistance of MDA-MB-435 cells (Yu et al., 1996) . This apparent discrepancy in Taxol resistance led us to suspect that other genetic alterations may contribute to Taxol resistance in BT483, MDA-MB-453, MDA-MB-361, SKBR-3, and BT474 cells.
mdr-1-encoded p170 is involved in Taxol resistance of the panel of established breast cancer cell lines
Overexpression of the p170 mdr-1 has been detected in many multidrug-resistant tumor cell lines and in a variety of tumors from cancer patients with both acquired and inherent drug resistance (Fojo et al., 1987; Goldstein et al., 1989; Moscow and Cowan, 1988; Nooter and Herweijer, 1991) , and p170 mdr-1 has been shown to confer Taxol resistance in ovarian cancer cells (Berkova and Page, 1995) . The panel of breast cancer cell lines we tested for Taxol resistance was established from dierent breast cancer patients, and some of them had been treated with chemotherapy that can select for p170 mdr-1 overexpressing cells. Therefore, we asked whether the breast cancer cells 
Overexpression of p185 c-erbB2 contributes to Taxol resistance in the panel of established breast cancer cell lines
Since both p185 c-erbB2 and p170 mdr-1 have been shown to confer Taxol resistance (Berkova and Page, 1995; Yu et al., 1996) , we asked whether overexpression of p185 c-erbB2 or p170 mdr-1 or both contributed to Taxol resistance. We ®rst examined whether p185 c-erbB2 overexpression contributed to Taxol resistance in the panel of breast cancer cell lines. We speci®cally downregulated cell-surface p185 c-erbB2 protein in p185 c-erbB2 -overexpressing MDA-MB-361 and BT-474 breast cancer cells by treating these cells with anti-p185 c-erbB2 monoclonal antibodies N29 and examining Taxol sensitivity. N29 was chosen because it speci®cally recognizes the N-terminal extracellular domain of the human p185 c-erbB2 protein, downregulates cell-surface p185 c-erbB2 , and translocates p185 c-erbB2 to cytoplasmic and perinuclear sites (Bacus et al., 1992) . Further, it has tumor-inhibitory potential, that correlates with its capacity to induce cellular dierentiation in human breast cancer cells (Bacus et al., 1992) . In three independent cytotoxicity assays, the N29 antibody sensitized MDA-MB-361 and BT-474 cells to Taxol (Figure 3 , left panels). The most signi®cant sensitization eects occurred at Taxol concentrations near the IC 50 , which is approximately 6 mM for MDA-MB-361 cells, 7 mM for BT-474 cells. However, N29 had no signi®cant eect on the Taxol sensitivity of MDA-MB-231 and MDA-MB-435 cells, which do not overexpress p185 c-erbB2 (Figure 3 , right panels). N29 antibody alone had little eect on survival of MDA-MB-361 and BT-474 cells and it inhibited cell growth by less than 10% (data not shown). Therefore, the signi®cant reduction in the survival rate of MDA-MB-361 and BT-474 cells treated with Taxol plus N29 antibody was mainly caused by increased Taxol sensitivity and not growth inhibition by the N29 antibody. The control c-neu-Ab-3 anti-p185 c-erbB2 antibody, which does not induce downregulation of p185 c-erbB2 , did not signi®cantly change the cytotoxicity of Taxol in these breast cancer cells (Figure 3 ). In addition, c-neu-Ab-5, which also induces downregulation of cell-surface p185 c-erbB2 but does not inhibit cell growth, sensitized MDA-MB-361 and BT-474 cells to Taxol treatment as well (data not shown). Western blot analysis of p185 c-erbB2 proteins from lysates of N29 antibody-treated, c-neu-Ab3 antibody-treated and untreated MDA-MB-361 and BT-474 cells (Figure 4a ) con®rmed that N29 antibody indeed down-regulated p185 c-erbB2 in both MDA-MB-361 and BT-474 cells, whereas the c-neu Ab-3 antibody did not. These results strongly suggest that, in the p185-overexpressing breast cancer cells, the p185 protein was necessary to induce Taxol resistance.
It has been previously reported that two c-erbB2 tyrosine kinase inhibitors (tyrphostin and emodin) can sensitize p185 c-erbB2 -overexpressing lung cancer cells to a variety of chemotherapeutic agents (Tsai et al., 1996; Zhang and Hung, 1996) , implying that the tyrosine kinase activity is important for c-erbB2 mediated chemoresistance. We therefore investigated whether down-regulation of p185 c-erbB2 by N29 antibody may result in lower tyrosine kinase activity. Western blot analysis with antiphosphotyrosine antibodies indicated that N29 antibody treatment reduced p185 c-erbB2 The IC 50 was de®ned as the concentration of the drug that reduced the survival of the treated cells to 50% of that in control cells and was obtained from dose-survival curves of three independent experiments. 
Overexpression of p170
mdr-1 also contributes to Taxol resistance in the panel of established breast cancer cell lines
The mdr-1 gene-encoded P-glycoprotein (p170 mdr-1 ) is a transmembrane transport protein that functions as drug-eux pump, reducing drug accumulation and thereby conferring resistance to a variety of chemotherapeutic drugs (Moscow and Cowan, 1988;  Figure 3 p185-speci®c monoclonal antibody N29 sensitizes p185-overexpressing breast cancer cells to Taxol. The indicated breast cancer cells (1.5610 4 ) in 0.1 ml culture medium were plated onto 96-well plates. 24 h later, cells were grown in either 100 ml fresh medium as drug-free control, or 100 ml fresh medium containing dierent concentrations of Taxol, or 100 ml fresh medium containing the same Taxol concentrations plus 1 mg c-neu-Ab-3 antibody, or 100 ml fresh medium containing the same Taxol concentrations plus 1 mg N29 antibody. Cells were incubated at 378C in a 5% CO 2 atmosphere for 72 h, and the percentages of cells surviving from each groups relative to drug-free controls, de®ned as 100% survival, were determined as described in the Materials and methods section. Data represent an average of at least three dierent experiments. SD S for each point were less than 15% Volm, 1993; Nooter and Herweijer, 1991) . A dose of 1 mg/ml of thioridazine eectively blocks p170 mdr-1 function in sarcoma S180
cells (Eerth and Volm, 1993) , so we tested doses ranging from 1 mg/ml to 5 mg/ml in the p185-overexpressing breast cancer cells. The 4 mg/ml dose proved most eective and noncytotoxic yielding less than a 10% reduction in cell survival compared with media-alone controls (data not shown). Thioradazine (4 mg/ml) sensitized BT-474 and MDA-MB-361 cells to Taxol of dierent concentrations, the most signi®cant eects occurring at Taxol concentrations close to the IC 50 value (Figure 5a , left panels). Thioridazine had no signi®cant eect on the Taxol .
Discussion
In this study we have demonstrated that overexpression of both p185 c-erbB2 and p170 mdr-1 can render breast cancer cells resistant to Taxol. The resistance is more signi®cant than that induced by c-erbB2 overexpression alone or mdr-1 overexpression alone. We have shown that c-erbB2 speci®c monoclonal antibodies, which are known to induce downregulation of cellsurface p185 c-erbB2 , sensitized p185 c-erbB2 overexpressing MDA-MB-361 and BT-474 breast cancer cells to Taxol. This indicates that p185 c-erbB2 protein expression is necessary for Taxol resistance. In addition, the mdr-1 blockers thioridazine and verapamil sensitized the p170 mdr-1 and p185 c-erbB2 overexpressing breast cancer cells to Taxol, which indicates that higher expression levels of p170 mdr-1 also contributes to Taxol resistance in these established breast cancer cell lines. Higher expression levels of p170 mdr-1 in these established breast cancer cell lines may explain the signi®cant dierences in the level of Taxol resistance between these established breast cancer cell lines (more than 100-fold increase) and the 435.eB transfectants (5 ± 9-fold increase) although they express similar levels of p185 c-erbB2
. Some of the established breast cancer cell lines may have been exposed to 2610 4 ) in 0.1 ml culture medium were plated onto 96-well plates. 24 h later, cells were grown in either 100 ml fresh medium as drug-free control, or in 100 ml fresh medium containing dierent concentrations of Taxol, or 100 ml fresh medium containing the same concentrations of Taxol plus 1 mg/ml thioridazine (Thiol), or 100 ml fresh medium containing the same concentrations of Taxol plus 4 mg/ml thioridazine (Thio4). Cells were incubated for 72 h, and the percentage of surviving cells relative to drug-free controls, de®ned as 100% survival, were determined. Data represent an average of at least four dierent experiments. SD S for each point were less than 12%. (b) Thioridazine treatment did not alter the p185 c-erbB2 or p170 mdr-1 protein level in breast cancer cells. Immumoblot analysis for the p185 c-erbB2 proteins in the cell lysates of the MDA-MB-361 and BT-474. Cells treated with or without 1 mg/ml or 4 mg/ml of thioridazine. 100 mg of protein from each sample was electrophoresed on 6% SDS ± PAGE and transferred to nitrocellulose ®lter. The ®lter was incubated with the primary monoclonal antibody c-neu-Ab-3 against p185 c-erbB2 or polyclonal antibody against p170 mdr-1 . Position of the p185 c-erbB2 and p170 mdr-1 are indicated on the left. The protein levels of b-actin were determined with anti-b-actin antibody as loading references . Taken together, our data indicate that both p170 mr-1 and p185 c-erbB2 pathways are invovled in the Taxol resistance of these breast cancer cells.
Although overexpression of either c-erbB2-encoded p185 protein or mdr-1-encoded p170 has been found in many types of human cancers and has been shown to lead to increased drug resistance, this is the ®rst report clearly demonstrating the biological consequence of p185 c-erbB2 and p170 mdr-1 co-overexpression in breast cancer cells. The c-erbB2 gene-encoded growth factor receptor synergized with the mdr-1 drug eux pump, leading to Taxol resistance. Our data emphasize an important notion, that when studying the functional role of an oncogene in cancer biology, one should investigate not only the eect of the oncogene per se, but also the interaction, cooperation, and synergism between the oncogene and other genetic alterations.
Co-overexpression of p170 mdr-1 and p185 c-erbB2 was found in the panel of established breast cancer cell lines used in this study. It is unlikely that the higher p170 mdr-1 expression in these Taxol resistant cells was the result of p185 c-erbB2 overexpression, since our previous results clearly indicated that overexpression of p185 c-erbB2 in 435.eB cells did not upregulate mdr-1 expression and p185 c-erbB2 overexpression can confer Taxol resistance via mdr-1-independent mechanisms. Interestingly, a statistically signi®cant association was reported between the expression of p185 c-erbB2 and p170 mdr-1 in mammary carcinomas (Schneider et al., 1994) . It is not yet clear whether this was a coincident correlation or if p185 c-erbB2 up-regulated p170 mdr-1 (or vice versa). Our ®ndings that p170 mdr-1 expression was not changed in 435.eB transfectants would argue against p185 c-erbB2 regulation of mdr-1-encoded p170 (Yu et al., 1996) , although we cannot rule out the possibility that p185 c-erbB2 may regulate mdr-1-encoded p170 mdr-1 in other breast cancer cells than MDA-MB-435 cells, given that speci®c genetic changes in MDA-MB-435 cells might interfere with the p170 mdr-1 regulatory pathway. However, downregulation of p185 c-erbB2 by N29 or c-neu-Ab-5 antibodies in MDA-MB-361 and BT-474 cells did not lead to discernible changes in p170 mdr-1 level (Figure 4c) , the results indicate that p170 mdr-1 expression is unlikely regulated by p185 c-erbB2 . Further investigation on the relationship between p185 c-erbB2 and p170 mdr-1 is needed to resolve this issue.
We have shown that signi®cant sensitization to Taxol can be achieved by either down-regulation of p185 c-erbB2 with anti-c-erbB2 antibody or by blocking of p170 mdr-1 using mdr-1 blocker in Taxol resistant breast cancer cells that overexpress both p185 c-erbB2 and p170 mdr-1 . These ®ndings have important clinical implications, since associated overexpression of both p170 mdr-1 and p185 c-erbB2 has been reported in a clinical study of mammary carcinomas (Schneider et al., 1994) . Our results suggest that combination therapy (i.e. cerbB2 receptor-targeting, blocking p170 mdr-1 plus chemotherapy) may be more eective for patients whose tumors express high levels of both p185 c-erbB2 and p170 mdr-1 .
Materials and methods
Cell line and culture
All human breast cancer cell lines used in this study were obtained from the American Type Culture Collection (Rockville, MD). Cells were grown in DME/F12 medium (GIBCO, Grand Island, NY) supplemented with 10% FBS (GIBCO). HBL-100 cells were derived from the milk of a nursing mother 3 days after delivery; MDA-MB-231 cells, MDA-MB-435 cells, and SKBR-3 cells were isolated from pleural eusions of patients with breast carcinoma. BT483 cells were isolated from a papillary invasive ductal tumor obtained from a patient with a family history of breast cancer. MDA-MB-361 cells were isolated from a brain metastasis of a breast cancer. MDA-MB-453 cells were isolated from eusion of a patient with metastatic breast carcinoma. BT-474 cells were derived from a solid, invasive ductal breast carcinoma (Hay et al., 1992) .
Immunoblotting
Immunoblot analyses were performed as described previously (Yu et al., 1990) . The primary antibodies used were monoclonal antibody c-neu-Ab-3 against the c-erbB2-encoded p185 protein, polyclonal antibody mdr-Ab-1 against mdr-1-encoded p170 P-glycoprotein, monoclonal antibody recognizing phosphorylated tyrosine (Oncogene Science, Inc, Uniondall, NY), and monoclonal antibody recognizing b-actin (Sigma, St Louis, MO). The blots were then incubated with horseradish peroxidase-conjugated goat anti-mouse immunoglobulin for the monoclonal antibodies and goat anti-rabbit immunoglobulin for the polyclonal primary antibodies (Bio-Rad Laboratories, Richmond, CA). Protein signals were detected with ECL chemiluminescence Western blotting detection reagents (Amersham, UK).
Cytotoxicity assay
Cells were plated onto 96-well plates, 8000 cell/well for each breast cancer cell line. Twenty-four hours later, the culture medium was replaced by fresh medium containing Taxol (Bristol-Myers Co/Mead Johnson Company, Princeton, NJ) or Taxotere (Rhone-Poulenc Rorer, Inc, Ft Washington, PA) at concentrations ranging from 0 to 30 mM, the cells were incubated for another 72 h, and the percentages of viable cells were determined by reduction of MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt), relative to drug-free controls, using the CellTiter96 TM AQ nonradioactive cell proliferation assay (Promega Corp, Madison, WI). All cytotoxicity data shown are the means of at least three independent experiments.
Antibody treatment of breast cancer cells
The c-erbB2 speci®c N29 monoclonal antibody was a generous gift from Dr Sarah S Bacus of Advanced Cellular Diagnostics, Inc (Elmhurst, IL), and the c-neu-Ab-3 and cneu-Ab-5 monoclonal antibodies were purchased from Oncogene Science Inc. These antibodies were puri®ed and reconstituted in PBS. The antibodies were added to the cell culture at a ®nal concentration of 1 mg/0.1 ml for 3 days for cytotoxicity assays.
Blocking of p170
mdr-1 in breast cancer cells Thioridazine {10-[2-(1methyl-2-piperidyl)ethyl]-2-[methylthio]phenothiazine} and verapamil were purchased from Sigma Chemical Co. Thioridazine was dissolved in PBS at a concentration of 100 mg/ml, and verapamil was dissolved in 100% ethanol at a concentration of 250 mg/ml. These
Taxol resistance of p170 mdr-1 -and p185 c-erbB2 -overexpressing cells D Yu et al stock solutions were then diluted to desired concentrations (1 mg/ml to 5 mg/ml) with DME/F12 medium supplemented with 10% FBS. Thioridazine and verapamil were added with Taxol at dierent concentrations to breast cancer cells for 3 days before cytotoxicity assays were performed.
